Guardant Health announced the initiation of a new study to examine patient preference for Shield, Guardant Health’s blood test to screen for colorectal cancer, or CRC, and if having the option of a blood test improves patient adherence to screening. The study will be conducted by the Center for Asian Health Equity – University of Chicago Medicine, or CAHE-UCM.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GH:
- Guardant Health gets coverage from UHC for Guardant360 in lung, breast cancer
- Guardant Health, AnHeart Therapeutics team on NSLC companion diagnostics
- Guardant Health ‘pleased’ with ruling in Illumina case
- FDA okays Guardant360 as companion diagnostic in patients with ESR1 mutations
- Sell these stocks now, proven algorithm says
